The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.
All Keywords
【저자키워드】 COVID-19, variants, Neutralizing, BNT162b2 vaccination, C.37 (Lambda Variants), 【초록키워드】 SARS-CoV-2, vaccination, susceptibility, variant, Infection, Transmission, virus, BNT162b2, Spread, mRNA, Lineage, wild type, BNT162b2 mRNA, Lambda, individual, titre, vaccinated individuals, vaccinated individual, neutralisation assays, European, neutralising, spread to, demonstrated, reduction in, 【제목키워드】 SARS-CoV-2, vaccination, variant, neutralisation, Lambda, Efficiency,
【저자키워드】 COVID-19, variants, Neutralizing, BNT162b2 vaccination, C.37 (Lambda Variants), 【초록키워드】 SARS-CoV-2, vaccination, susceptibility, variant, Infection, Transmission, virus, BNT162b2, Spread, mRNA, Lineage, wild type, BNT162b2 mRNA, Lambda, individual, titre, vaccinated individuals, vaccinated individual, neutralisation assays, European, neutralising, spread to, demonstrated, reduction in, 【제목키워드】 SARS-CoV-2, vaccination, variant, neutralisation, Lambda, Efficiency,
처음에 페루에서 확인된 SARS-CoV-2 람다(Pango 혈통 지정 C.37) 변종은 추가 국가로 확산되었습니다. 아르헨티나와 여러 유럽 국가에서 수입된 후 2021년 4월 이스라엘에서 처음 발견된 람다 변종은 더 이상의 확산 없이 두 개의 주요 전송 체인에 속한 18명의 개인을 감염시켰습니다. Comirnaty(BNT162b2 mRNA, BioNTech-Pfizer) 백신 접종 후 미세 중화 분석은 야생형 바이러스와 비교하여 중화 역가에서 유의한 1.6배 감소를 보여 백신 접종된 개인의 감염 감수성이 증가했음을 시사합니다.